Direct Flow Medical has announced it closed a new round of financing totaling $32 million.

Direct Flow Medical, headquartered in Santa Rosa, Calif., is a developer of transcatheter heart valve technologies.

The financing rounds includes $17 million in PE, led by new investor SV Life Sciences, and the second tranche of a $50 million debt facility from PDL BioPharma worth $15 million.

Direct Flow Medical indicated the financing will be used to complete a trial and support growth of the company’s products outside of the U.S.